1:00 PM - 1:15 PM (EDT), Monday, June 5, 2023 ・ Session Room 104B
OculoTherapy is an early-stage start-up with a novel IOP-lowering eye drop for use in patients with primary open angle glaucoma or ocular hypertension. We demonstrated that topical administration of our eye drops engineered to include bioadhesive and extended-release properties reduced IOP in mice and rabbits in a dose-dependent manner with efficacy and duration that were equal to or greater than those reported for currently available medications, while concomitantly offering a much-needed new mechanism of action. We have recently filed our pre-IND meeting request with the FDA and are seeking guidance on our chemistry, manufacturing and controls, nonclinical and clinical development plans. Because our API is a repurposed FDA approved drug, we plan to use the 505(b)(2) regulatory pathway. We have reached this stage of development with non-dilutive funding and hope to seek strategic partnership and outside investment to carry us through Phase 2 clinical trials.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
novel extended release IOP lowering eye drop
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Founder and CSO